Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00181688 · ClinicalTrials.gov registry record · Phase 2
Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer
A Phase 2 study of Ovarian Cancer and Peritoneal Carcinoma, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 2
- Study locations
NCT00181688 is a Phase 2 study of Ovarian Cancer and Peritoneal Carcinoma that has completed, run by Massachusetts General Hospital. The registered enrollment target is 35 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00181688, a Phase 2 study of Ovarian Cancer and Peritoneal Carcinoma, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 2
- Study locations
Study Summary
The main purpose of this study is to determine the effects (good and bad) Iressa plus anastrozole has on patients with relapsed ovarian cancer.
Conditions Studied
Interventions
- DRUG Iressa (ZD1839)
- DRUG Arimidex (Anastrozole)
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2003-10 |
| Est. Completion | 2006-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00181688
The ClinicalTrials.gov registry entry for NCT00181688 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Iressa (ZD1839) is the first listed.
NCT00181688 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00181688 about?
NCT00181688 is a clinical study titled "Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer". The main purpose of this study is to determine the effects (good and bad) Iressa plus anastrozole has on patients with relapsed ovarian cancer.
What is the current status of trial NCT00181688?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2003-10. Estimated completion is 2006-03.
What conditions does trial NCT00181688 study?
This clinical trial studies the following conditions: Ovarian Cancer, Peritoneal Carcinoma, Tubal Carcinoma.
What interventions are being tested in trial NCT00181688?
The interventions under investigation include: Iressa (ZD1839) (DRUG), Arimidex (Anastrozole) (DRUG).
Who is sponsoring clinical trial NCT00181688?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00181688 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.